332 related articles for article (PubMed ID: 16036178)
1. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
Cubie HA; Moore C; Waller M; Moss S;
J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.
Engesæter B; van Diermen Hidle B; Hansen M; Moltu P; Staby KM; Borchgrevink-Persen S; Vintermyr OK; Lönnberg S; Nygård M; Janssen EA; Castle PE; Christiansen IK
BMC Infect Dis; 2016 Nov; 16(1):698. PubMed ID: 27881082
[TBL] [Abstract][Full Text] [Related]
4. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
5. HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.
Carozzi FM; Del Mistro A; Cuschieri K; Frayle H; Sani C; Burroni E
J Clin Virol; 2016 Mar; 76 Suppl 1():S22-S28. PubMed ID: 26669512
[TBL] [Abstract][Full Text] [Related]
6. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.
Kuebler DL; Illingworth A; Blenc AM; Wilbur DC
Cancer; 2007 Oct; 111(5):339-43. PubMed ID: 17879373
[TBL] [Abstract][Full Text] [Related]
7. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting.
Carozzi FM; Del Mistro A; Confortini M; Sani C; Puliti D; Trevisan R; De Marco L; Tos AG; Girlando S; Palma PD; Pellegrini A; Schiboni ML; Crucitti P; Pierotti P; Vignato A; Ronco G
Am J Clin Pathol; 2005 Nov; 124(5):716-21. PubMed ID: 16203283
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
9. Development of a pilot proficiency program for human papillomavirus DNA detection.
Costa AG; Escott R; Garland SM; Byers D; Tabrizi SN
Pathology; 2018 Oct; 50(6):659-664. PubMed ID: 30139535
[TBL] [Abstract][Full Text] [Related]
10. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
11. Primary human papillomavirus testing in organized cervical screening.
Dillner J
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):11-6. PubMed ID: 23299089
[TBL] [Abstract][Full Text] [Related]
12. VALGENT: A protocol for clinical validation of human papillomavirus assays.
Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
[TBL] [Abstract][Full Text] [Related]
13. Laboratory audit as part of the quality assessment of a primary HPV-screening program.
Hortlund M; Sundström K; Lamin H; Hjerpe A; Dillner J
J Clin Virol; 2016 Feb; 75():33-6. PubMed ID: 26748032
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
17. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
18. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient groups.
Yeoh GP; Tse MP; Chan KW; Lord L
Acta Cytol; 2006; 50(6):627-31. PubMed ID: 17152273
[TBL] [Abstract][Full Text] [Related]
20. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
